CompletedPhase 1
Randomized, double-blind, placebo-controlled study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of pitolisant after repeated oral ascending doses for 14 days, including the pitolisant effect on cardiac repolarization in healthy volunteers.
Key facts
- Phase
- Phase 1
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Trial details
- Who runs it
- Bioprojet Pharma
- Trial code
- EU 2023-503945-78-00
- Record updated
- 26 July 2024